These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19763106)

  • 1. New approaches to drug safety: a pharmacovigilance tool kit.
    Wise L; Parkinson J; Raine J; Breckenridge A
    Nat Rev Drug Discov; 2009 Oct; 8(10):779-82. PubMed ID: 19763106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond debacle and debate: developing solutions in drug safety.
    Ray A
    Nat Rev Drug Discov; 2009 Oct; 8(10):775-9. PubMed ID: 19763107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance: a science or fielding emergencies?
    Evans SJ
    Stat Med; 2000 Dec; 19(23):3199-209. PubMed ID: 11113954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 9. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FDA and safety--beyond the heparin crisis.
    Laurencin CT; Nair L
    Nat Biotechnol; 2008 Jun; 26(6):621-3. PubMed ID: 18536680
    [No Abstract]   [Full Text] [Related]  

  • 11. Canaries, coal mines and the drug supply.
    Leiden JM
    Nat Biotechnol; 2008 Jun; 26(6):624-6. PubMed ID: 18536681
    [No Abstract]   [Full Text] [Related]  

  • 12. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.
    Spelsberg A; Prugger C; Doshi P; Ostrowski K; Witte T; Hüsgen D; Keil U;
    BMJ; 2017 Feb; 356():j337. PubMed ID: 28174182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What you don't know will hurt you.
    Nat Biotechnol; 2008 Jun; 26(6):589. PubMed ID: 18536658
    [No Abstract]   [Full Text] [Related]  

  • 14. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 15. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.
    Lu CY
    Clin Rheumatol; 2009 Apr; 28(4):371-7. PubMed ID: 19190976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study.
    Akinola S; da Silveira CG; Corbin S; Lavallée M; Thibault M; Gonella J; Gimenes FRE; Leclerc J
    Pharmaceut Med; 2020 Aug; 34(4):263-269. PubMed ID: 32671791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary by a child psychiatrist in industry on the assessment of drug safety.
    Allen AJ
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):288-91. PubMed ID: 17630860
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.